Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415142 | 0.78 | ALDH1A1 (0.43) | ALDH1A1POLBLMNA | |
| SCHEMBL23414676 | 0.70 | LMNA (0.33) | ALDH1A1GRM5LMNA | |
| SCHEMBL23414533 | 0.69 | FADS1 (0.55) | — | |
| SCHEMBL23415103 | 0.67 | XDH (0.43) | ALDH1A1LMNA | |
| SCHEMBL23327679 | 0.65 | LMNA (0.35) | ALDH1A1POLBGRM5LMNA | |
| SCHEMBL6920833 | 0.65 | NPC1 (0.43) | ALDH1A1POLBGRM5LMNA | |
| SCHEMBL23444324 | 0.65 | — | — | |
| SCHEMBL11723346 | 0.64 | POLB (0.34) | ALDH1A1POLBLMNA | |
| SCHEMBL23415119 | 0.64 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23522363 | 0.63 | TSHR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | ALDH1A1 326/4885POLB 2016/4885GRM5 828/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | ALDH1A1 326/4885POLB 2016/4885GRM5 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.